Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease

Time: 12:30 pm
day: Track B - Day 1 AM


  • Harnessing the power of fluid biomarkers and imaging modalities as diagnostic and theragnostic biomarkers in drug development for Alzheimer’s disease
  • Revealing novel Alzheimer’s biomarkers used in modification trials and understanding their impact on disease modification trials
  • Comparing and contrasting CSF versus plasma biomarkers on disease progression and severity